Jiangsu Hengrui Medicine
600276.SS
#437
Rank
โ‚น4.906 T
Marketcap
โ‚น739.18
Share price
-0.34%
Change (1 day)
37.16%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2025 (TTM): โ‚น100.64 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are โ‚น4.19 Billion. In 2024 the company made an earning of โ‚น91.94 Billion, an increase over its 2023 earnings that were of โ‚น61.05 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) โ‚น100.64 B9.47%
2024 โ‚น91.94 B50.59%
2023 โ‚น61.05 B11.35%
2022 โ‚น54.82 B-13.82%
2021 โ‚น63.61 B-34.16%
2020 โ‚น96.61 B16.28%
2019 โ‚น83.09 B32.92%
2018 โ‚น62.51 B20.82%
2017 โ‚น51.74 B23.8%
2016 โ‚น41.79 B11.25%
2015 โ‚น37.56 B39.52%
2014 โ‚น26.92 B20.71%
2013 โ‚น22.30 B11.46%
2012 โ‚น20.01 B29.6%
2011 โ‚น15.44 B31.28%
2010 โ‚น11.76 B27.89%
2009 โ‚น9.19 B5.84%
2008 โ‚น8.69 B79.89%
2007 โ‚น4.83 B32.93%
2006 โ‚น3.63 B38.14%
2005 โ‚น2.63 B21.56%
2004 โ‚น2.16 B13.95%
2003 โ‚น1.89 B38.06%
2002 โ‚น1.37 B